Paroxysmal Nocturnal Hemoglobinuria: Disease-Characteristics Report

Executive summary

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, non-Mendelian clonal hematopoietic stem-cell disorder. A somatic loss-of-function mutation—usually in PIGA—prevents biosynthesis of the glycosylphosphatidylinositol (GPI) anchor. Consequently, affected blood cells lack GPI-anchored complement regulators, especially CD55/decay-accelerating factor and CD59, and become susceptible to complement-mediated injury. The defining clinical spectrum comprises chronic or episodic intravascular hemolysis, thrombosis, and variable bone-marrow failure. Modern complement inhibitors have greatly improved survival, but residual anemia, breakthrough hemolysis, infection risk, adherence, marrow failure, and access remain important unmet needs. (panse2024paroxysmalnocturnalhemoglobinuria pages 1-2, versino2024complementinhibitionin pages 2-2, colden2022insightsintothe pages 1-3)

The following table provides a compact knowledge-base summary; ontology accessions marked for validation should be checked directly against the current source ontology before production ingestion.

Table: This compact table summarizes core disease facts for paroxysmal nocturnal hemoglobinuria, including cause, mechanism, phenotypes, diagnosis, epidemiology, treatment advances, prognosis, and model systems. It also flags ontology mappings and identifiers that should be independently validated before database ingestion.

1. Disease information

Definition, identifiers, and synonyms

Preferred name: paroxysmal nocturnal hemoglobinuria. Synonyms: paroxysmal nocturnal haemoglobinuria, PNH, Marchiafava–Micheli disease, and Strübing–Marchiafava disease. The historical name is imperfect: hemolysis is not necessarily paroxysmal, nocturnal, or accompanied by visible hemoglobinuria.

Commonly assigned identifiers are OMIM 300818, Orphanet ORPHA:447, ICD-10-CM D59.5, and MeSH D006457. A commonly used MONDO mapping is MONDO:0012727, but all identifiers—particularly the current ICD-11 and MONDO releases—should be verified against the live terminology service before database release.

This report concerns aggregated disease-level evidence from peer-reviewed studies, international registries, consensus literature, and trials. It is not derived from an individual patient’s EHR. The International PNH Registry analysis included 4,439 patients and is therefore population-level observational evidence. (schrezenmeier2020baselineclinicalcharacteristics pages 1-2)

2. Etiology, risks, and protective factors

Primary cause

Classic PNH is caused by an acquired somatic, not inherited, loss-of-function mutation in PIGA, an X-linked gene at Xp22. PIGA participates in the first step of GPI-anchor synthesis in the endoplasmic reticulum. Because only one active X chromosome is present in each hematopoietic cell, a single somatic hit can produce the phenotype. Hundreds of private mutations have been reported—including small insertions/deletions, substitutions, nonsense, frameshift, and splice-altering lesions—with no dominant hotspot; one sequencing series found 26 PIGA mutations among 33 patients and identified exon 2 as the most frequently affected region. (versino2024complementinhibitionin pages 2-3, chen2021advancesinthe pages 1-3)

PIGA mutation is necessary but generally insufficient for clinically overt PNH. Tiny GPI-deficient populations, approximately 0.001–0.005%, can occur in healthy people, whereas expanded clones occur in nearly half of patients with immune-mediated acquired aplastic anemia. The leading “escape” model proposes that autoreactive T-cell pressure suppresses normal hematopoiesis while GPI-deficient hematopoietic stem/progenitor cells enjoy relative survival—not an autonomous proliferative advantage. Mouse and macaque experiments support this interpretation because mutant cells reconstitute hematopoiesis but do not progressively dominate. (colden2022insightsintothe pages 1-3)

Risk and modifier factors

• Strong clinical context: acquired aplastic anemia and other immune-mediated marrow-failure states. Clone evolution can occur during recovery after immunosuppression. (colden2022insightsintothe pages 1-3)
• Clone size: larger granulocyte clones generally correlate with hemolysis, high disease activity, and thrombosis, although clinically important events occur even with clones below 10%. (schrezenmeier2020baselineclinicalcharacteristics pages 1-2)
• Physiologic complement-amplifying conditions: infection, trauma, surgery, pregnancy, and other inflammatory states can precipitate pharmacodynamic breakthrough hemolysis. (versino2024complementinhibitionin pages 1-2, hillmen2024navigatingthecomplement pages 7-9)
• Additional somatic variants: exploratory studies have reported variants in genes including TET2, CUX1, SUZ12, RBPJ, MUC4, MLL2/KMT2D, and others. Their causal or prognostic roles are not sufficiently validated for routine PNH risk stratification. RBPJ knockdown increased apoptosis and reduced proliferation in patient-derived cells in vitro, but in-vivo confirmation is lacking. (chen2021advancesinthe pages 1-3)
• Thrombophilia alleles: factor V Leiden and MTHFR polymorphisms have been examined, but a disease-modifying causal effect remains unproven. (risitano2008paroxysmalnocturnalhemoglobinuria pages 3-4)

No reproducible dietary, lifestyle, occupational, toxin, infectious-agent, or environmental cause has been established. There are likewise no validated inherited protective alleles or lifestyle measures that prevent acquisition of PNH. Avoiding infection and promptly treating complement-amplifying conditions reduces complications rather than preventing the initial clone.

3. Phenotypes

PNH may present from childhood to late adulthood but is predominantly an adult-onset disease, with median diagnosis around 35–40 years. Severity is highly variable; manifestations are chronic with episodic exacerbations. (panse2024paroxysmalnocturnalhemoglobinuria pages 1-2, yu2024healthrelatedqualityof pages 1-2)

Principal phenotypes and suggested HPO annotations

• Coombs-negative intravascular hemolytic anemia: anemia, reticulocytosis, elevated LDH and indirect bilirubin, low haptoglobin, plasma-free hemoglobin, and hemoglobinuria/hemosiderinuria. Suggested HPO: Hemolytic anemia, Intravascular hemolysis, Reticulocytosis, Elevated lactate dehydrogenase, Hemoglobinuria. (versino2024complementinhibitionin pages 3-4)
• Fatigue and exercise intolerance: fatigue occurred in 80.9–81% of registry patients; dyspnea occurred in 45.3%. Suggested HPO: Fatigue, Exercise intolerance, Dyspnea. (panse2024paroxysmalnocturnalhemoglobinuria pages 1-2, schrezenmeier2020baselineclinicalcharacteristics pages 3-5)
• Hemoglobinuria: reported by 45.0%; it may be episodic and is neither required nor always nocturnal. Suggested HPO: Hemoglobinuria. (schrezenmeier2020baselineclinicalcharacteristics pages 3-5)
• Smooth-muscle dystonia: abdominal pain (35.2%), dysphagia, esophageal spasm, and erectile dysfunction arise largely from nitric-oxide depletion. Suggested HPO: Abdominal pain, Dysphagia, Erectile dysfunction. (versino2024complementinhibitionin pages 3-4, schrezenmeier2020baselineclinicalcharacteristics pages 3-5)
• Thrombosis: venous events predominate and frequently involve unusual sites—hepatic/Budd–Chiari, portal, mesenteric, splenic, or cerebral veins. Thrombosis may be the first manifestation and historically affected up to approximately 40% of patients. Suggested HPO: Venous thrombosis, Budd-Chiari syndrome, Cerebral venous thrombosis. (panse2024paroxysmalnocturnalhemoglobinuria pages 1-2)
• Bone-marrow failure/cytopenias: aplastic anemia, pancytopenia, neutropenia, and thrombocytopenia may precede, accompany, or follow hemolytic PNH. Bone-marrow failure was recorded in 62.6% of the large registry cohort. Suggested HPO: Bone marrow hypocellularity, Pancytopenia, Thrombocytopenia, Neutropenia. (schrezenmeier2020baselineclinicalcharacteristics pages 1-2)
• Renal disease: acute kidney injury during hemolytic crises and chronic impairment from repeated hemoglobin filtration, hemosiderin deposition, tubular injury, and vascular dysfunction; registry impaired renal function was 42.8%. Suggested HPO: Renal insufficiency, Acute kidney injury, Hemosiderinuria. (schrezenmeier2020baselineclinicalcharacteristics pages 1-2, apostolidou2025paroxysmalnocturnalhemoglobinuria pages 1-2)
• Pulmonary/vascular disease: pulmonary hypertension and dyspnea can follow NO depletion, hemolysis, and thromboembolism. Suggested HPO: Pulmonary hypertension. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 1-2)

Clinical categories include classic hemolytic PNH, PNH associated with another marrow disorder, subclinical PNH, and a proposed ahemolytic/“white PNH” phenotype with a sizable clone but little biochemical hemolysis. Clone-size boundaries are descriptive rather than absolute treatment criteria. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 2-4)

Quality of life

A 2024 Chinese cross-sectional study of 329 patients found anxiety/depression problems in 81.5%, pain/discomfort in 69.9%, mean EQ-5D-5L utility 0.76, and mean EQ-VAS 62.61. Anemia symptoms, back pain, hemoglobinuria, thrombosis, sex, and income influenced HRQoL. Diagnostic burden is also substantial: fewer than 40% have historically been diagnosed within 12 months of symptom onset, while 24% waited at least five years. (yu2024healthrelatedqualityof pages 1-2)

4. Genetic and molecular information

Causal gene: PIGA; the relevant lesions are somatic variants in a multipotent hematopoietic stem cell. They are absent from the constitutional germline in ordinary PNH and therefore should not be interpreted using population carrier frequency or Mendelian penetrance concepts. Germline PIGA variants instead cause a distinct congenital disorder of GPI-anchor biosynthesis, not classic PNH.

Most pathogenic PNH variants produce partial or complete loss of function. Type III cells completely lack GPI-anchored proteins and are much more complement-sensitive; type II cells retain partial expression; type I cells are phenotypically normal. Flow cytometry—not germline variant classification—is the clinically decisive assay. (kelly2025pharmacologicaltherapiesin pages 1-2, versino2024complementinhibitionin pages 3-4)

No recurrent chromosomal abnormality defines PNH. Cytogenetic or myeloid-gene abnormalities may indicate associated MDS or clonal evolution and should be interpreted as comorbidity/modification rather than the defining lesion. WES/WGS may detect PIGA or secondary variants but is not first-line diagnostic testing.

Epigenetic, single-cell, spatial-transcriptomic, proteomic, metabolomic, and lipidomic signatures are not sufficiently standardized for clinical annotation. Current omics work is chiefly exploratory; no omics-based diagnostic has displaced flow cytometry.

5. Environmental information

PNH is not caused by a pathogen, toxin, diet, smoking, alcohol, radiation, or occupation. Infection, surgery, trauma, and pregnancy can increase complement activation and trigger hemolysis in an existing clone. These are triggers/modifiers, not primary causes. There is no zoonotic transmission or infectious reservoir. (versino2024complementinhibitionin pages 1-2, hillmen2024navigatingthecomplement pages 7-9)

6. Mechanism and pathophysiology

Upstream causal chain

1. A somatic PIGA lesion occurs in a hematopoietic stem cell.
2. Defective ER GPI-anchor synthesis prevents surface attachment of nearly 150 GPI-linked proteins.
3. Descendant erythrocytes, granulocytes, monocytes, and platelets lack CD55 and CD59.
4. CD55 loss impairs decay of C3/C5 convertases; CD59 loss permits C5b-9 membrane-attack-complex assembly.
5. Constitutive alternative-pathway “tick-over,” factor B/factor D amplification, and terminal complement activation lyse PNH erythrocytes. (versino2024complementinhibitionin pages 2-3, colden2022insightsintothe pages 1-3)

Downstream injury

Intravascular hemolysis releases free hemoglobin, which scavenges nitric oxide. NO depletion causes vasoconstriction and smooth-muscle dystonia, explaining abdominal pain, dysphagia, erectile dysfunction, fatigue, and part of the pulmonary hypertension phenotype. Hemoglobin/iron filtration causes renal tubular hemosiderosis and dysfunction. (risitano2008paroxysmalnocturnalhemoglobinuria pages 3-4, apostolidou2025paroxysmalnocturnalhemoglobinuria pages 1-2)

Thrombosis is multifactorial: complement-mediated platelet and endothelial activation, procoagulant microparticles, leukocyte activation, tissue-factor and inflammatory signaling, impaired fibrinolysis—including possible loss of GPI-anchored uPAR—and NO depletion reinforce coagulation. The complement and coagulation systems form a bidirectional amplification loop. (risitano2008paroxysmalnocturnalhemoglobinuria pages 3-4, fattizzo2026thrombosisinparoxysmal pages 1-2, apostolidou2025paroxysmalnocturnalhemoglobinuria pages 1-2)

Under C5 blockade, C3 fragments may accumulate on surviving PNH erythrocytes and mark them for hepatic/splenic phagocytosis, causing C3-mediated extravascular hemolysis. Proximal inhibitors at C3, factor B, or factor D address this mechanism. (kelly2025pharmacologicaltherapiesin pages 1-2, hillmen2024navigatingthecomplement pages 7-9)

Suggested annotations include GO GPI-anchor biosynthetic process, complement activation, alternative pathway, membrane attack complex assembly, erythrocyte homeostasis, nitric oxide metabolic process, and blood coagulation; CL hematopoietic stem cell, erythrocyte, monocyte, neutrophil, platelet, endothelial cell, and macrophage.

7. Anatomical structures affected

The primary compartment is bone marrow hematopoiesis and circulating blood. Directly affected cell lineages include erythrocytes, granulocytes, monocytes, and platelets. Secondary organs include the kidney, liver and splanchnic venous system, cerebral veins, lungs/pulmonary vasculature, spleen, and gastrointestinal tract. No lateralization applies. Subcellular compartments include the ER/Golgi GPI-biosynthetic pathway, plasma membrane, extracellular complement cascade, and MAC. Suggested UBERON mappings: bone marrow, blood, kidney, liver, spleen, lung, pulmonary artery, portal vein, hepatic vein, and cerebral venous system.

8. Temporal development

Onset is usually insidious in young-to-middle adulthood, although pediatric and geriatric disease occurs. The clone may remain small and asymptomatic, expand during immune marrow failure, produce chronic hemolysis with episodic crises, regress, or coexist with persistent aplasia. Small clones should be monitored because clinical burden is not zero: among clones below 10%, registry rates were 9.7% for hemolysis, 10.2% for major adverse vascular events, and 9.1% for high disease activity. (schrezenmeier2020baselineclinicalcharacteristics pages 1-2)

PNH is generally chronic. Spontaneous clonal contraction/remission can occur, but the timing is unpredictable. Critical intervention windows include active hemolysis, new thrombosis, pregnancy, major surgery, infection, transfusion dependence, and worsening marrow failure.

9. Inheritance, epidemiology, and population

PNH has no Mendelian inheritance pattern, carrier state, anticipation, founder effect, consanguinity association, or conventional germline penetrance. Familial recurrence is not expected, and routine cascade or reproductive genetic screening is inappropriate for classic PNH.

Reported estimates vary with ascertainment: prevalence is commonly 10–20 per million, with broader estimates of 13–38 per million; incidence is often approximately 1–1.5 per million/year. A 2024 review cited incidence 0.08–0.57 per 100,000 person-years and prevalence about 38 per million. There is no consistent sex, race, ethnicity, or geographic predilection, although ascertainment and access differ markedly. (panse2024paroxysmalnocturnalhemoglobinuria pages 1-2, yu2024healthrelatedqualityof pages 1-2)

In the 4,439-patient registry, 51.6% had high disease activity, 18.8% a major adverse vascular event, 62.6% marrow failure, 61.3% prior RBC transfusion, and 42.8% impaired renal function. (schrezenmeier2020baselineclinicalcharacteristics pages 1-2)

10. Diagnostics

Recommended approach

High-sensitivity multiparameter flow cytometry on peripheral blood is the diagnostic gold standard. Demonstrate deficient GPI-linked proteins in at least two lineages. Granulocyte/monocyte assays commonly combine FLAER with CD24, CD14, CD157, CD15, CD45, and/or CD64; RBC assays use CD235a gating with CD59 and sometimes CD55. Granulocyte and monocyte clone sizes best estimate the stem-cell clone because transfusion and hemolysis can underestimate RBC clones. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 2-4, almakadi2025clinicalcharacteristicsand pages 4-6)

Initial laboratory evaluation includes CBC/differential, reticulocytes, blood smear, LDH, bilirubin, haptoglobin, plasma-free hemoglobin, urinalysis, renal function, iron indices, and direct antiglobulin testing. Bone-marrow aspirate/biopsy and cytogenetic/myeloid NGS evaluation are indicated when aplastic anemia, MDS, or unexplained cytopenias are suspected.

Screen appropriate patients with acquired aplastic anemia; unexplained Coombs-negative hemolysis; hemoglobinuria; unexplained cytopenias; MDS with hypocellularity; thrombosis at unusual sites; or thrombosis accompanied by hemolysis/cytopenia. Historical Ham and sucrose-lysis tests are obsolete except in legacy reports.

Differential diagnosis

Exclude autoimmune hemolytic anemia, hereditary membrane/enzyme defects, microangiopathic hemolysis, cold-antibody disease, mechanical hemolysis, march hemoglobinuria, infection-associated hemolysis, and other marrow-failure/MDS syndromes. PNH is distinguished by a reproducible GPI-deficient clone across blood lineages.

WES, WGS, single-gene sequencing, CMA, FISH, karyotyping, mtDNA, and repeat-expansion tests are not routine confirmatory tests for PNH. Population, newborn, carrier, prenatal, and preimplantation screening are not indicated.

11. Outcomes and prognosis

Before complement inhibition, thrombosis was the leading cause of death and retrospective estimates included approximately 35% five-year mortality and 50% ten-year mortality. Contemporary complement therapy has transformed prognosis; a review cited 95.5% five-year survival with eculizumab and reduction in thrombotic events from 5.6 to 0.8 per 100 patient-years. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 1-2, perry2025theadvancinglandscape pages 3-4)

Poor prognostic factors include prior thrombosis, large/expanding clone, severe hemolysis, transfusion dependence, renal impairment, pulmonary hypertension, persistent cytopenias, severe aplastic anemia, MDS/AML evolution, and inadequate complement control. Residual anemia may reflect extravascular hemolysis, breakthrough intravascular hemolysis, iron deficiency, renal dysfunction, or marrow failure.

12. Treatment and recent developments

Complement-directed therapy

• Eculizumab, anti-C5 monoclonal antibody, FDA-approved in 2007, suppresses MAC-mediated intravascular hemolysis and substantially reduces transfusion, thrombosis, renal injury, and mortality. Limitations are intravenous dosing every two weeks, C3-mediated extravascular hemolysis, and breakthrough hemolysis. Suggested MAXO: complement-inhibitor therapy; monoclonal-antibody therapy. (versino2024complementinhibitionin pages 2-2, perry2025theadvancinglandscape pages 3-4)
• Ravulizumab, recycled long-acting anti-C5 antibody, permits approximately eight-week dosing. Phase III studies established noninferiority to eculizumab; review data report transfusion avoidance of 73.6% versus 66.1% and breakthrough hemolysis of 4.0% versus 10.7%. (perry2025theadvancinglandscape pages 3-4)
• Pegcetacoplan, subcutaneous C3/C3b inhibitor approved in 2021, inhibits proximal and terminal activation and controls both intravascular and C3-mediated extravascular hemolysis. PEGASUS showed superiority to eculizumab for persistent anemia; PRINCE supported use in complement-inhibitor-naïve disease. Injection-site reactions are common. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 6-8, hillmen2024navigatingthecomplement pages 7-9)
• Iptacopan, oral factor-B inhibitor, received FDA approval on 6 December 2023. In 2024 APPLY-PNH, 51/60 patients switching from anti-C5 achieved a ≥2-g/dL hemoglobin increase and 42/60 reached hemoglobin ≥12 g/dL without transfusion, versus 0/35 continuing anti-C5. In APPOINT-PNH, 31/33 untreated patients achieved a ≥2-g/dL increase without transfusion. Transfusion avoidance was 59/62 versus 14/35 in APPLY; no APPOINT patient required transfusion. Headache was the most frequent adverse event. Trials: NCT04558918 and NCT04820530; published 14 March 2024, DOI https://doi.org/10.1056/NEJMoa2308695. (latour2024oraliptacopanmonotherapy pages 1-4)
• Danicopan, oral factor-D inhibitor, is used as add-on therapy to anti-C5 in selected patients with clinically significant extravascular hemolysis/residual anemia. It targets alternative-pathway amplification while preserving established terminal blockade. (versino2024complementinhibitionin pages 1-2)
• Crovalimab, a recycling subcutaneous anti-C5 antibody, showed noninferiority to eculizumab in the COMMODORE program and offers less frequent administration. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 6-8)

All complement inhibitors increase susceptibility to invasive infection—especially Neisseria meningitidis and, depending on the breadth of blockade, other encapsulated bacteria such as pneumococcus and Haemophilus influenzae. Vaccination should precede treatment when feasible; urgent therapy should not be delayed when clinically necessary, but antibiotic prophylaxis and local regulatory guidance should then be followed. Vaccination does not eliminate risk, so fever or meningococcal symptoms require emergency evaluation. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 6-8)

Treatment strategy

Treat clinically significant hemolysis, symptomatic anemia, thrombosis, organ injury, transfusion dependence, or high disease activity—not clone size alone. A C5 inhibitor remains appropriate for robust intravascular control; proximal inhibition is attractive for residual C3-mediated anemia or oral/subcutaneous convenience. There was no universally accepted evidence-based first-line algorithm in 2024; selection should incorporate marrow reserve, hemolysis type, thrombosis history, adherence, pregnancy, infection risk, route, availability, and cost. (panse2024paroxysmalnocturnalhemoglobinuria pages 1-2)

Supportive measures include phenotype-matched RBC transfusion, folate and iron replacement when deficient, treatment of infection, renal support, and careful avoidance of unnecessary corticosteroids. Anticoagulation is indicated for acute thrombosis, generally together with complement inhibition; duration should be individualized. Registry baseline use included transfusion in 61.3%, anticoagulation in 20.2%, and immunosuppression in 38.8%. (schrezenmeier2020baselineclinicalcharacteristics pages 3-5)

Allogeneic hematopoietic stem-cell transplantation is the only established curative therapy but carries substantial treatment-related morbidity and mortality. It is generally reserved for severe marrow failure, clonal evolution/MDS, or selected refractory disease rather than uncomplicated complement-responsive hemolysis. Suggested MAXO: hematopoietic stem-cell transplantation. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 1-2)

No validated pharmacogenomic genotype currently selects among complement inhibitors. PIGA variant class itself does not determine drug choice.

Pregnancy

Pregnancy raises hemolytic and thrombotic risk and requires specialist hematology–maternal-fetal care. A systematic review of 190 pregnancies found fetal survival of 82% with eculizumab versus 69% without it; miscarriage was twice as frequent without treatment, and preterm delivery occurred in 32% versus 44%. Evidence was predominantly observational/case-series level, so confounding remains. (manning2025paroxysmalnocturnalhaemoglobinuria pages 1-3)

13. Prevention

There is no primary prevention for the spontaneous somatic PIGA event. No population, newborn, carrier, or family screening program is appropriate.

Secondary prevention consists of timely flow-cytometric testing in high-risk clinical contexts, serial clone monitoring in aplastic anemia/MDS, and early treatment of active hemolysis or thrombosis. Tertiary prevention comprises complement inhibition, vaccination, infection education, thrombosis management, renal monitoring, perioperative planning, and management of pregnancy and inflammatory triggers. Genetic counseling should explain the acquired, non-heritable nature of classic PNH rather than offer familial predictive testing.

14. Other species and natural disease

No well-established naturally occurring veterinary counterpart of human clonal PNH was identified. PIGA and the GPI-anchor pathway are evolutionarily conserved, but classic PNH is not zoonotic and has no cross-species transmission. Mouse Piga and rhesus PIGA are the principal orthologous experimental targets; exact NCBI Gene and taxon identifiers should be validated directly before database ingestion.

15. Model organisms

Conditional/chimeric Piga-knockout mice, erythroid-specific knockout models, and CRISPR-edited rhesus macaques generate GPI-AP-deficient lineages. They reproduce shortened erythrocyte survival and increased complement sensitivity, making them useful for studying GPI biology, immune selection, and complement therapeutics. However, they generally fail to develop the sustained clone expansion, overt hemolysis, and thrombosis characteristic of human PNH. (colden2022insightsintothe pages 1-3, chen2021advancesinthe pages 1-3)

This limitation is mechanistically informative: the dedicated animal-model review concludes that “the PIG-A mutation is one of the several conditions required for PNH, but it alone is not enough to cause PNH.” Likewise, the 2022 review states that mutant cells “have no intrinsic growth advantage and do not clonally expand over time.” These are review-abstract quotations synthesizing mouse and nonhuman-primate evidence, not direct human clinical findings. (colden2022insightsintothe pages 1-3, chen2021advancesinthe pages 1-3)

Cellular systems include patient-derived CD59-negative blood/HSPC populations, engineered PIGA-null cell lines, and complement-sensitive erythroid assays. Their limitations include absence of marrow immune selection, whole-organism complement–coagulation interactions, and thrombosis. MGI, IMSR/MMRRC, NCBI Gene, and nonhuman-primate research repositories are appropriate model-resource starting points.

Evidence limitations and authoritative interpretation

The strongest human evidence comprises flow-confirmed clinical cohorts, the International PNH Registry, randomized complement-inhibitor trials, and recent expert reviews. Exact phenotype frequencies vary with referral pattern, clone threshold, therapy exposure, and geographic access. The 2024 expert position is that terminal inhibitors dramatically improve survival, whereas proximal inhibitors improve residual anemia and quality of life; nevertheless, long-term comparative effectiveness and first-line selection require more real-world data. (panse2024paroxysmalnocturnalhemoglobinuria pages 1-2)

Mechanistic statements about immune escape, secondary mutations, platelet/endothelial pathways, and animal models combine human observational, in-vitro, and model-organism evidence and should not all be assigned equal causal certainty. Robust PNH-specific spatial transcriptomic, single-cell atlas, epigenomic, lipidomic, or clinically validated multi-omic signatures remain unavailable in the retrieved evidence.

References

1. (panse2024paroxysmalnocturnalhemoglobinuria pages 1-2): Jens Peter Panse, Britta Höchsmann, and Jörg Schubert. Paroxysmal nocturnal hemoglobinuria, pathophysiology, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:310-320, Aug 2024. URL: https://doi.org/10.1159/000540474, doi:10.1159/000540474. This article has 14 citations and is from a peer-reviewed journal.

2. (versino2024complementinhibitionin pages 2-2): Francesco Versino and Bruno Fattizzo. Complement inhibition in paroxysmal nocturnal hemoglobinuria: from biology to therapy. International Journal of Laboratory Hematology, 46:43-54, Apr 2024. URL: https://doi.org/10.1111/ijlh.14281, doi:10.1111/ijlh.14281. This article has 33 citations and is from a peer-reviewed journal.

3. (colden2022insightsintothe pages 1-3): Melissa A. Colden, Sushant Kumar, Bolormaa Munkhbileg, and Daria V. Babushok. Insights into the emergence of paroxysmal nocturnal hemoglobinuria. Frontiers in Immunology, Jan 2022. URL: https://doi.org/10.3389/fimmu.2021.830172, doi:10.3389/fimmu.2021.830172. This article has 46 citations and is from a peer-reviewed journal.

4. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 1-2): Elisavet Apostolidou, Vasileios Georgoulis, Dimitrios Leonardos, Eleni Kapsali, and Eleftheria Hatzimichael. Paroxysmal nocturnal hemoglobinuria: unraveling its molecular pathogenesis and advancing targeted therapeutic strategies. Diseases, Sep 2025. URL: https://doi.org/10.3390/diseases13090298, doi:10.3390/diseases13090298. This article has 4 citations.

5. (versino2024complementinhibitionin pages 1-2): Francesco Versino and Bruno Fattizzo. Complement inhibition in paroxysmal nocturnal hemoglobinuria: from biology to therapy. International Journal of Laboratory Hematology, 46:43-54, Apr 2024. URL: https://doi.org/10.1111/ijlh.14281, doi:10.1111/ijlh.14281. This article has 33 citations and is from a peer-reviewed journal.

6. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 2-4): Elisavet Apostolidou, Vasileios Georgoulis, Dimitrios Leonardos, Eleni Kapsali, and Eleftheria Hatzimichael. Paroxysmal nocturnal hemoglobinuria: unraveling its molecular pathogenesis and advancing targeted therapeutic strategies. Diseases, Sep 2025. URL: https://doi.org/10.3390/diseases13090298, doi:10.3390/diseases13090298. This article has 4 citations.

7. (versino2024complementinhibitionin pages 2-3): Francesco Versino and Bruno Fattizzo. Complement inhibition in paroxysmal nocturnal hemoglobinuria: from biology to therapy. International Journal of Laboratory Hematology, 46:43-54, Apr 2024. URL: https://doi.org/10.1111/ijlh.14281, doi:10.1111/ijlh.14281. This article has 33 citations and is from a peer-reviewed journal.

8. (chen2021advancesinthe pages 1-3): Yingying Chen and Fu Rong. Advances in the creation of animal models of paroxysmal nocturnal hemoglobinuria. Hematology, 26:491-496, Jan 2021. URL: https://doi.org/10.1080/16078454.2021.1945244, doi:10.1080/16078454.2021.1945244. This article has 7 citations and is from a peer-reviewed journal.

9. (versino2024complementinhibitionin pages 3-4): Francesco Versino and Bruno Fattizzo. Complement inhibition in paroxysmal nocturnal hemoglobinuria: from biology to therapy. International Journal of Laboratory Hematology, 46:43-54, Apr 2024. URL: https://doi.org/10.1111/ijlh.14281, doi:10.1111/ijlh.14281. This article has 33 citations and is from a peer-reviewed journal.

10. (risitano2008paroxysmalnocturnalhemoglobinuria pages 3-4): A. Risitano and B. Rotoli. Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents. Biologics : Targets & Therapy, 2:205-222, Jun 2008. URL: https://doi.org/10.2147/btt.s1420, doi:10.2147/btt.s1420. This article has 134 citations.

11. (hillmen2024navigatingthecomplement pages 7-9): Peter Hillmen, Regina Horneff, Michael Yeh, Martin Kolev, and Pascal Deschatelets. Navigating the complement pathway to optimize pnh treatment with pegcetacoplan and other currently approved complement inhibitors. International Journal of Molecular Sciences, 25:9477, Aug 2024. URL: https://doi.org/10.3390/ijms25179477, doi:10.3390/ijms25179477. This article has 21 citations.

12. (schrezenmeier2020baselineclinicalcharacteristics pages 1-2): Hubert Schrezenmeier, Alexander Röth, David J. Araten, Yuzuru Kanakura, Loree Larratt, Jamile M. Shammo, Amanda Wilson, Gilda Shayan, and Jaroslaw P. Maciejewski. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (pnh): updated analysis from the international pnh registry. Annals of Hematology, 99:1505-1514, May 2020. URL: https://doi.org/10.1007/s00277-020-04052-z, doi:10.1007/s00277-020-04052-z. This article has 197 citations and is from a peer-reviewed journal.

13. (schrezenmeier2020baselineclinicalcharacteristics pages 3-5): Hubert Schrezenmeier, Alexander Röth, David J. Araten, Yuzuru Kanakura, Loree Larratt, Jamile M. Shammo, Amanda Wilson, Gilda Shayan, and Jaroslaw P. Maciejewski. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (pnh): updated analysis from the international pnh registry. Annals of Hematology, 99:1505-1514, May 2020. URL: https://doi.org/10.1007/s00277-020-04052-z, doi:10.1007/s00277-020-04052-z. This article has 197 citations and is from a peer-reviewed journal.

14. (yu2024healthrelatedqualityof pages 1-2): Huaxin Yu, Shengnan Duan, Pei Wang, Rong Fu, Zixuan Lv, Yuchi Yu, Pu Miao, Junwei Shi, Niekun Zhuang, Huiying Hu, Ni Yuan, and Sijia Che. Health-related quality of life and influencing factors of patients with paroxysmal nocturnal hemoglobinuria in china. Orphanet Journal of Rare Diseases, May 2024. URL: https://doi.org/10.1186/s13023-024-03178-x, doi:10.1186/s13023-024-03178-x. This article has 4 citations and is from a peer-reviewed journal.

15. (almakadi2025clinicalcharacteristicsand pages 4-6): Mohammed Almakadi, Noura AlHashim, Murtadha Al-Khabori, Hazzaa Alzahrani, Hani Yousif Osman, Mervat Mattar, and Ahmed Sabah. Clinical characteristics and management of paroxysmal nocturnal hemoglobinuria in the middle east: a narrative review. Clinical and Experimental Medicine, Aug 2025. URL: https://doi.org/10.1007/s10238-025-01834-5, doi:10.1007/s10238-025-01834-5. This article has 0 citations and is from a peer-reviewed journal.

16. (latour2024oraliptacopanmonotherapy pages 1-4): Régis Peffault de Latour, Alexander Röth, Austin G. Kulasekararaj, Bing Han, Phillip Scheinberg, Jaroslaw P. Maciejewski, Yasutaka Ueda, Carlos M. de Castro, Eros Di Bona, Rong Fu, Li Zhang, Morag Griffin, Saskia M.C. Langemeijer, Jens Panse, Hubert Schrezenmeier, Wilma Barcellini, Vitor A.Q. Mauad, Philippe Schafhausen, Suzanne Tavitian, Eloise Beggiato, Lee Ping Chew, Anna Gaya, Wei-Han Huang, Jun Ho Jang, Toshio Kitawaki, Abdullah Kutlar, Rosario Notaro, Vinod Pullarkat, Jörg Schubert, Louis Terriou, Michihiro Uchiyama, Lily Wong Lee Lee, Eng-Soo Yap, Flore Sicre de Fontbrune, Luana Marano, Ferras Alashkar, Shreyans Gandhi, Roochi Trikha, Chen Yang, Hui Liu, Richard J. Kelly, Britta Höchsmann, Cécile Kerloeguen, Partha Banerjee, Rafael Levitch, Rakesh Kumar, Zhixin Wang, Christine Thorburn, Samopriyo Maitra, Shujie Li, Aurelie Verles, Marion Dahlke, and Antonio M. Risitano. Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 390:994-1008, Mar 2024. URL: https://doi.org/10.1056/nejmoa2308695, doi:10.1056/nejmoa2308695. This article has 142 citations and is from a highest quality peer-reviewed journal.

17. (apostolidou2025paroxysmalnocturnalhemoglobinuria pages 6-8): Elisavet Apostolidou, Vasileios Georgoulis, Dimitrios Leonardos, Eleni Kapsali, and Eleftheria Hatzimichael. Paroxysmal nocturnal hemoglobinuria: unraveling its molecular pathogenesis and advancing targeted therapeutic strategies. Diseases, Sep 2025. URL: https://doi.org/10.3390/diseases13090298, doi:10.3390/diseases13090298. This article has 4 citations.

18. (perry2025theadvancinglandscape pages 3-4): Cameron Perry, Xinyu von Buttlar, and Swapna Thota. The advancing landscape of paroxysmal nocturnal hemoglobinuria treatment. Turkish Journal of Hematology, 42:74-81, Apr 2025. URL: https://doi.org/10.4274/tjh.galenos.2025.2025.0054, doi:10.4274/tjh.galenos.2025.2025.0054. This article has 2 citations.

19. (kelly2025pharmacologicaltherapiesin pages 1-2): Richard J. Kelly, Matthew Holt, and Jeff Szer. Pharmacological therapies in paroxysmal nocturnal haemoglobinuria: focus on complement inhibition. Drugs, 85:1413-1428, Sep 2025. URL: https://doi.org/10.1007/s40265-025-02235-4, doi:10.1007/s40265-025-02235-4. This article has 3 citations and is from a domain leading peer-reviewed journal.

20. (fattizzo2026thrombosisinparoxysmal pages 1-2): Bruno Fattizzo and Christoph Q. Schmidt. Thrombosis in paroxysmal nocturnal hemoglobinuria in the complement inhibitor era: mechanisms, risk stratification, and clinical management. International Journal of Hematology, Mar 2026. URL: https://doi.org/10.1007/s12185-026-04190-6, doi:10.1007/s12185-026-04190-6. This article has 1 citations and is from a peer-reviewed journal.

21. (manning2025paroxysmalnocturnalhaemoglobinuria pages 1-3): James E. Manning, Etienne Ciantar, Morag Griffin, and Richard J. Kelly. Paroxysmal nocturnal haemoglobinuria in pregnancy–a systematic review with meta analysis. Annals of Hematology, 104:2517-2525, Apr 2025. URL: https://doi.org/10.1007/s00277-025-06353-7, doi:10.1007/s00277-025-06353-7. This article has 7 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00